Alley-oop
1 month ago
$ENDV NO OS CHNAGE
ENDV Security Details
Share Structure
Market Cap Market Cap
435,097 01/03/2025
Authorized Shares
2,500,000,000 01/03/2025
Outstanding Shares
543,871,313 01/03/2025
Restricted
195,293,179 01/03/2025
Unrestricted
348,578,134 01/03/2025
Alley-oop
1 month ago
Summary of Endonovoโs Restructured Business Model
Focus on Digital Health and AI Integration:
Endonovo Therapeutics (ENDV) is reorganizing to develop an integrated AI-powered digital healthcare and wellness platform.
The platform aims to enhance patient engagement, streamline access for healthcare providers, and expand retail sales of wellness and medical products.
Expansion into the Wellness Market:
ENDV is entering the $4.3 trillion global wellness market (projected to reach $7 trillion by 2025) with a focus on e-commerce.
Its platform will feature AI-integrated e-commerce for wellness products, including the companyโs Pulsed Electro Magnetic Field (PEMF) multi-coil technology.
Market Potential and AI Differentiation:
The digital health market, valued at $375.99 billion in 2022, is projected to grow to $1.965 trillion by 2030 at a CAGR of 23.3%.
ENDV's AI integration will provide advanced analytics, predictive marketing, and enhanced customer engagement, setting its platform apart from competitors.
Strategic Goals:
Transform patient care across medical and wellness industries.
Utilize AI for better insights into customer behavior, targeted marketing, and efficient customer support.
Company Structure:
Digital Health and Wellness Division: Focused on the AI-powered platform and e-commerce marketplace.
Legacy Division: Developer of non-invasive wearable Electroceutical® devices for general wellness.
Biotech_Tradez
1 month ago
LOL! Repeating the same BS as the last pump and dumper!
This company's contraption doesn't work like they said it did. It lacks real studies. All their scientists left to start their own competitor company as Craig previously posted. They originally were going to acquire this technology for $28 million, then sued and bought it for $4.5 million which is probably what it was worth and proceeded to destroy all its value by proving they couldn't sell the product, dropping the concussion studies, and suing their competitors and failing. So, how on God's green earth is the valuation supposed to suddenly increase over 10x what they paid for it? I guess they plan to sprinkle fairy dust on it.
It has been a year and they still have not gotten it done, guess why? Nobody will issue a valuation for them because they could get sued. Nobody is going to finance it to go onto NASDAQ. It takes around $10 million to get on. Lastly, the debt holders will be the fist to dump the shares in order to get their money, which they will convert to freely traded shares long before any retail investor can. This is another one of the CEO's scams to keep milking money out of investors.
Alley-oop
1 month ago
1. Will SofPulse Be Public or Private?
Initial Status: SofPulse, Inc. will remain private at the time of acquisition completion.
Future Plans:
SofPulse intends to meet the regulatory requirements for a NASDAQ listing, suggesting that it plans to become a publicly traded company in the near future.
2. If SofPulse Is Going Public, Will They Have an IPO or Buy a Shell?
Likely Approach:
Based on the announcement, SofPulse plans to go public through a direct listing or IPO on NASDAQ. This process involves filing with the SEC and meeting NASDAQ's listing criteria.
There is no indication of using a reverse merger with a shell company, though it could remain an option if a direct listing proves challenging.
3. Would ENDV Shareholders Get Restricted SofPulse Shares? If Restricted, When/How Can They Sell?
Restricted Shares:
The shares issued to ENDV shareholders will likely be restricted, meaning they cannot be sold immediately upon receipt.
Restriction Period: Restricted shares typically have a lock-up period (commonly 6โ12 months) during which they cannot be traded.
Selling Process:
After the restriction period expires, shareholders may need to comply with Rule 144 of the Securities Act to sell their shares, including filing appropriate documentation.
4. If ENDV Shareholders Get a Dividend... Where Will the New SofPulse Entity Get $40 Million?
Source of Funds:
Stock, Not Cash: The $40 million dividend will be issued in SofPulse restricted stock, not cash. SofPulse, Inc. is not required to have $40 million in cash on hand to fulfill this
commitment.
Capital Raise: SofPulse plans to raise up to $500,000 in a pre-money valuation of $10 million. Future funding rounds or operational revenue may support the valuation and company growth.
Valuation-Linked Payment:
If the updated third-party valuation exceeds $50 million, the additional amount will be paid through a senior note convertible into NASDAQ-listed marketable securities.
Alley-oop
1 month ago
$ENDV Benefits for Common Shareholders from the SofPulse Transaction
Stock Dividend or Alternative Mechanism:
As part of the agreement, 80% of the $50 million in restricted stock (priced at $5.00 per share) from SofPulse, Inc. will be issued to Endonovoโs (ENDV) shareholders. This provides a direct benefit to common shareholders, effectively transferring a portion of the value from the sale to them.
Potential Uplisting to NASDAQ:
SofPulse, Inc. has committed to fulfilling regulatory requirements for a NASDAQ listing. This uplisting could significantly increase the liquidity and perceived value of the issued shares, benefiting shareholders holding the restricted stock.
Additional Valuation-Based Payments:
A third-party valuation may determine the assets' value to be higher than $50 million (up to $100 million). The difference will be issued to ENDV in the form of a senior note, which could further increase the benefits distributed to shareholders.
Strengthened Future Prospects:
SofPulseโs plans for substantial growth, including:
Expanding Federal Supply Schedule contracts with the VA and Department of Defense.
Developing international markets.
Targeting annual revenues of $100 million by 2025.
Shareholders may benefit if the company achieves these projections and their issued shares gain value over time.
ENDV's Continued Operations:
ENDV will retain its telehealth division and mergers/acquisitions division, providing shareholders with additional growth opportunities in other sectors.
Capital Raise and Strategic Expansion:
SofPulseโs $500,000 capital raise at a pre-money valuation of $10 million may position the company for sustained growth, indirectly supporting shareholder value.
Alley-oop
1 month ago
$ENDV SofPulse, a FDA Cleared medical device company specializing in non-invasive microcurrent therapy, has undergone several valuations in recent years:
2018 Valuation: A third-party assessment valued SofPulse's intellectual property and assets at $75 million.
2023 Agreement: Endonovo Therapeutics, the parent company, entered into a definitive agreement to sell SofPulse's business and medical intellectual property to SofPulse, Inc. for a minimum of $50 million. The final purchase price is subject to an updated valuation by a qualified third party, with estimates ranging between $50 million to $100 million.